Antibody Or Fragment Thereof Whose Amino Acid Sequence Is Disclosed In Whole Or In Part Patents (Class 424/800)
  • Patent number: 8992924
    Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: March 31, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
  • Patent number: 8980270
    Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: March 17, 2015
    Assignee: iPierian, Inc.
    Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
  • Patent number: 8815242
    Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: August 26, 2014
    Assignee: Synageva BioPharma Corp.
    Inventor: Alex J. Harvey
  • Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Patent number: 8529902
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: September 10, 2013
    Assignee: Genmab A/S
    Inventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
  • Patent number: 8475793
    Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: July 2, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Leonard G. Presta
  • Patent number: 8470327
    Abstract: Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: June 25, 2013
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Robert Heinz Edward Friesen, Theodorus Hendrikus Jacobus Kwaks, Mandy Antonia Catharina Jongeneelen
  • Patent number: 8465741
    Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: June 18, 2013
    Assignee: MMRGlobal, Inc.
    Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
  • Patent number: 8337844
    Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Merck Patent GmbH
    Inventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
  • Patent number: 8323653
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: December 4, 2012
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Patent number: 8216581
    Abstract: The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others. Preferably, the antibody is an unglycosylated H44L4 Fab.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: July 10, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Donald L. Siegel
  • Patent number: 8147832
    Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: April 3, 2012
    Assignee: Merck Patent GmbH
    Inventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
  • Patent number: 8133483
    Abstract: The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: March 13, 2012
    Assignee: Hansa Medical AB
    Inventors: Lars Björck, Rikard Holmdahl, Kutty Selva Nandakumar
  • Patent number: 7838041
    Abstract: The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: November 23, 2010
    Assignee: Immune System Therapeutics Ltd
    Inventors: Robert Lindsay Raison, Rosanne Dorothy Dunn, Boon Hwa Andre Choo
  • Patent number: 7514079
    Abstract: The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal disorders, anxiety, depression, addiction, or pain. The invention also relates to nucleic acid molecules encoding anti-neurokinin B antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: April 7, 2009
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, Steven M. Ruben
  • Patent number: 7422739
    Abstract: Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: September 9, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 7399471
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: July 15, 2008
    Assignee: ZLB Behring AG
    Inventors: Andreas Morell, Martin Imboden, Beda Stadler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
  • Patent number: 7364737
    Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: April 29, 2008
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
  • Patent number: 7041292
    Abstract: The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Genentech, Inc.
    Inventor: Mark X. Sliwkowski
  • Patent number: 6949245
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 27, 2005
    Assignee: Genentech, Inc.
    Inventor: Mark Sliwkowski
  • Patent number: 6793933
    Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to enhance the immune system (e.g., increase the activity of T and B lymphocytes and natural killer cells) in a mammal, said ability resulting from their having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using these compositions.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: September 21, 2004
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 6759055
    Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to improve kidney functions (e.g., restoring urine secretion and/or lowering blood urea nitrogen, serum proteinuria, and/or serum creatinine levels) in a subject as a result of having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making such compositions.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: July 6, 2004
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 6756050
    Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells have been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength for a period of time sufficient to increase the capability of said plurality of yeast cells to improve the memory of a mammal. Also included are methods of making such compositions.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 29, 2004
    Assignee: Ultra Biotech Limited
    Inventor: Larry Ling Yuk Cheung
  • Patent number: 6753008
    Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to normalize the serum level of GPT, AP and/or LDH-5 in a mammal, said ability resulting from their having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using these compositions.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 22, 2004
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 6685942
    Abstract: A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: February 3, 2004
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
  • Patent number: 6682734
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 2004
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 6509015
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., Kd=10−8 M or less), a slow off rate for hTNF&agr; dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: January 21, 2003
    Assignee: BASF Aktiengesellschaft
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 6491916
    Abstract: The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These “humanized” anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: December 10, 2002
    Assignees: Tolerance Therapeutics, Inc., Ortho Pharmaceutical Corporation
    Inventors: Jeffrey A. Bluestone, Robert A. Zivin, Linda K. Jolliffe
  • Patent number: 6312690
    Abstract: Cloning of DNA fragments which code for the light chain or the heavy chain variable domain of the D7C2 monoclonal antibody within a baculovirus. The invention also concerns the expression of these DNA fragments in insect host cells, the anti-rhesus D recombinant monoclonal antibody so obtained and its use.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: November 6, 2001
    Assignees: Institut Pasteur, Proteine Performance
    Inventors: Léna Edelman, Christel Margaritte, Michel Kaczorek, Hassan Chaabihi
  • Patent number: 5843439
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 5827534
    Abstract: An oral dosage composition for intestinal delivery of a therapeutic agent comprising:(A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and(B) an intestinal absorption enhancing effective amount of purified Vibrio cholera zonula occludens toxin.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: October 27, 1998
    Assignee: University of Maryland at Baltimore
    Inventor: Alessio Fasano
  • Patent number: 5776456
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 5760185
    Abstract: An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutralizing activity against FHV-1 was constructed, and a gene fragment coding for V region of said antibody responsible for the specific binding activity against FHV-1 was obtained. Using this gene fragment and a gene fragment coding for the constant region of a feline antibody, a chimeric anti-FHV-1 recombinant antibody is obtained.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: June 2, 1998
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Kazuhiko Kimachi, Hiroaki Maeda, Kiyoto Nishiyama, Sachio Tokiyoshi
  • Patent number: 5736137
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: April 7, 1998
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 5653980
    Abstract: The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a structurally stable unit of said amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent of the antigen specificity of the IgE molecule but will reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: August 5, 1997
    Inventor: Lars T. Hellman